Pernix Therapeutics Holdings Inc. (PTX)

2.38
0.06 2.50
NASDAQ : Health Technology
Prev Close 2.44
Open 2.39
Day Low/High 2.36 / 2.43
52 Wk Low/High 2.00 / 7.15
Volume 32.11K
Avg Volume 119.10K
Exchange NASDAQ
Shares Outstanding 11.87M
Market Cap 28.97M
EPS -7.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pernix Therapeutics Reports Second Quarter 2017 Financial Results And Provides Business Update

Pernix Therapeutics Reports Second Quarter 2017 Financial Results And Provides Business Update

Recently Completed Refinancing Transactions to Provide Company with up to $45 Million in Aggregate New Capital to Grow Company's Business

Pernix Commences Refinancing Transactions To Fortify Balance Sheet

Pernix Commences Refinancing Transactions To Fortify Balance Sheet

Transactions will Provide up to $45 Million in Aggregate New Capital to Grow Company's Business

Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results

Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results

Company Expects to Report Full Quarterly Financial Results and Host Conference Call on July 27, 2017

Pernix Therapeutics Reports First Quarter 2017 Financial Results And Provides Business Update

First Quarter Prescription Volumes Grew Year-Over-Year for Zohydro ER® with BeadTek™ and Silenor®

Pernix Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results

Fourth Quarter Prescription Volumes Grew Year-Over-Year for All Three Core Brands, Treximet®, Zohydro ER® with BeadTek™ and Silenor®

Pernix Therapeutics Appoints Two Board Members

Pernix Therapeutics Appoints Two Board Members

Regains Compliance with NASDAQ Listing Rule 5605(c)(2)(A)